Dexmedetomidine as Adjunctive Therapy for Alcohol Withdrawal
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
This study is designed to evaluate dexmedetomidine as adjunctive therapy of severe alcohol
withdrawal of medical ICU patients. Specifically, this study will assess whether adjunctive
dexmedetomidine reduces the doses of conventional agents used for alcohol withdrawal while
maintaining patient comfort and safety and will explore if dexmedetomidine exhibits a
dose-dependent profile of action when it is used for this indication. In addition, this study
will assess the relationships between alcohol withdrawal, therapy with dexmedetomidine, and
potential serum biomarkers of alcohol withdrawal.
Phase:
N/A
Details
Lead Sponsor:
University of Colorado, Denver
Collaborators:
Hospira, Inc. Hospira, now a wholly owned subsidiary of Pfizer